Published in Am Rev Respir Dis on April 01, 1981
An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun (1996) 9.21
Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1994) 3.92
Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med (2004) 2.46
Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol (2000) 2.03
Transcription of two sigma 70 homologue genes, sigA and sigB, in stationary-phase Mycobacterium tuberculosis. J Bacteriol (1999) 1.59
Transcription of the stationary-phase-associated hspX gene of Mycobacterium tuberculosis is inversely related to synthesis of the 16-kilodalton protein. J Bacteriol (1999) 1.57
Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 1.48
Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med (2001) 1.47
Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 1.21
Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol (2002) 1.14
Effects of recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin on infections of mouse peritoneal macrophages with Listeria monocytogenes and Mycobacterium microti in vitro. Br J Exp Pathol (1986) 1.12
Capreomycin is active against non-replicating M. tuberculosis. Ann Clin Microbiol Antimicrob (2005) 1.09
Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother (2009) 1.08
In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 1.05
Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery. Pharmaceuticals (Basel) (2010) 0.95
Antibiotic action on phagocytosed bacteria measured by a new method for determining viable bacteria. Antimicrob Agents Chemother (1984) 0.95
Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet (2015) 0.94
Cyclic AMP-dependent resuscitation of dormant Mycobacteria by exogenous free fatty acids. PLoS One (2013) 0.91
Assessment of the Efficacy of New Anti-Tuberculosis Drugs. Open Infect Dis J (2008) 0.91
A clinical approach to paediatric tuberculosis in Canada. Paediatr Child Health (2003) 0.88
Defensin production by human limbo-corneal fibroblasts infected with mycobacteria. Pathogens (2013) 0.83
Influence of BCG-induced immunity on the bactericidal activity of isoniazid and rifampicin in experimental tuberculosis of the mouse and guinea-pig. Br J Exp Pathol (1989) 0.81
Antituberculosis therapy for 2012 and beyond. Expert Opin Pharmacother (2012) 0.80
Pharmacokinetic mismatch of tuberculosis drugs. Antimicrob Agents Chemother (2012) 0.76
Current concepts in the treatment of tuberculosis. West J Med (1987) 0.75
Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ (1969) 12.55
A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol (1972) 6.78
Antigenic diversity of Mycobacterium tuberculosis and Mycobacterium bovis detected by means of monoclonal antibodies. Lancet (1981) 6.01
The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis (1980) 4.69
Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis (1999) 4.52
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis (2008) 3.77
The action of antituberculosis drugs in short-course chemotherapy. Tubercle (1985) 3.69
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis (1986) 3.46
Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis (2010) 3.07
Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis (1993) 3.01
Selective Kirchner medium in the culture of specimens other than sputum for mycobacteria. J Clin Pathol (1983) 2.61
Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid. Br Med J (1970) 2.61
Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis (1975) 2.59
The use of murine monoclonal antibodies without purification of antigen in the serodiagnosis of tuberculosis. J Immunol Methods (1982) 2.57
Quality control in tuberculosis bacteriology. 1. Laboratory studies on isolated positive cultures and the efficiency of direct smear examination. Tubercle (1980) 2.57
Selective media in the isolation of tubercle bacilli from tissues. J Clin Pathol (1973) 2.17
The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother (1993) 2.12
Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol (2000) 2.03
Basic mechanisms of chemotherapy. Chest (1979) 2.01
Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet (1988) 1.99
Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother (1996) 1.97
Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy. Tuber Lung Dis (1993) 1.94
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother (2000) 1.90
A computer-assisted bacteriology reporting and information system. J Clin Pathol (1978) 1.86
The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med (1997) 1.76
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis (2002) 1.73
An effective method of RNA extraction from bacteria refractory to disruption, including mycobacteria. Nucleic Acids Res (1997) 1.69
Primary drug resistance in pulmonary tuberculosis in Great Britain: second national survey, 1963. Tubercle (1966) 1.65
Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis (1992) 1.56
The correlation of bacteriophage types of Mycobacterium tuberculosis with guinea-pig virulence and in vitro-indicators of virulence. J Gen Microbiol (1978) 1.55
Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J Clin Microbiol (2000) 1.51
Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis. Am Rev Respir Dis (1977) 1.50
Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett (1998) 1.48
Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 1.48
Bioavailability of rifampin in experimental murine tuberculosis. Antimicrob Agents Chemother (1992) 1.48
Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle (1970) 1.45
Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis (1997) 1.44
Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle (1968) 1.43
Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle (1970) 1.41
Drug resistance in mycobacteria. Br Med Bull (1984) 1.40
Rifabutin in the treatment of newly diagnosed pulmonary tuberculosis. Tuber Lung Dis (1995) 1.39
HLA typing in the Hong Kong Chest Service/British Medical Research Council study of factors associated with the breakdown to active tuberculosis of inactive pulmonary lesions. Am Rev Respir Dis (1988) 1.38
Quality control in tuberculosis bacteriology. 2. The origin of isolated positive cultures from the sputum of patients in four studies of short course chemotherapy in Africa. Tubercle (1980) 1.36
In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle (1987) 1.35
Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J (1996) 1.34
The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis. Tuber Lung Dis (1995) 1.33
In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle (1987) 1.30
Laboratory aspects of intermittent drug therapy. Postgrad Med J (1971) 1.28
Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis (1998) 1.28
The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med (1997) 1.27
Amikacin in the treatment of pulmonary tuberculosis. Tubercle (1983) 1.23
Examination of sputum by smear and culture in case-finding. Bull Int Union Tuberc (1968) 1.23
Geographic distribution of bacteriophage types of Mycobacterium tuberculosis. Am Rev Respir Dis (1969) 1.23
Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 1.21
Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis (2006) 1.20
Influence of aging on the in vivo properties of human patellar tendon. J Appl Physiol (1985) (2008) 1.20
Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care Med (1998) 1.20
In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle (1987) 1.19
The therapy of pulmonary tuberculosis in Kenya: a comparison of the results achieved in controlled clinical trials with those achieved by the routine treatment services. Tubercle (1970) 1.18
Comparison of machine and manual staining of direct smears for acid-fast bacilli by fluorescence microscopy. J Clin Pathol (1976) 1.16
Role of lipid content and hydrogen peroxide susceptibility in determining the guinea-pig virulence of Mycobacterium tuberculosis. Br J Exp Pathol (1982) 1.13
Effects of recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin on infections of mouse peritoneal macrophages with Listeria monocytogenes and Mycobacterium microti in vitro. Br J Exp Pathol (1986) 1.12
The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis (1992) 1.11
Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol. Tubercle (1976) 1.10
Pyrazinamide and other drugs in tuberculous meningitis. Lancet (1973) 1.09
Examination of operation specimens from patients with spinal tuberculosis for tubercle bacilli. J Clin Pathol (1983) 1.08
Comparison of methods for testing the sensitivity of Mycobacterium tuberculosis to ethionamide. Tubercle (1966) 1.08
Standard smears for grading the content of acid-fast bacilli in sputum. Tubercle (1966) 1.07
Hemagglutination tests for tuberculosis with mycobacterial glycolipid antigens. Results in patients with active pulmonary tuberculosis before and during chemotherapy and in healthy tuberculosis contacts. Am Rev Respir Dis (1981) 1.06
Demonstration of increased anti-mycobacterial activity in peripheral blood monocytes after BCG vaccination in British school children. Clin Exp Immunol (1988) 1.05
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Br J Exp Pathol (1986) 1.05
Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tuber Lung Dis (1992) 1.04
Response to treatment with isoniazid plus PAS of tuberculous patients with primary isoniazid resistance. Tubercle (1969) 1.03
Counts of viable tubercle bacilli in sputum related to smear and culture gradings. Med Lab Sci (1992) 1.02
New antibacterial drugs for the treatment of mycobacterial disease in man. Br Med Bull (1988) 1.02
Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. J Chemother (2006) 1.02
Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int J Tuberc Lung Dis (2008) 1.02
The 45 kilodalton molecule of Mycobacterium tuberculosis identified by immunoblotting and monoclonal antibodies as antigenic in patients with tuberculosis. Br J Exp Pathol (1989) 1.01
Serodiagnosis of tuberculosis using an ELISA with antigen 5 and a hemagglutination assay with glycolipid antigens. Results in patients with newly diagnosed pulmonary tuberculosis ranging in extent of disease from minimal to extensive. Am Rev Respir Dis (1990) 1.00
Bacteriology of tuberculosis. Trop Doct (1974) 1.00
In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565). Tubercle (1990) 0.99
Treatment of tuberculosis. The Mitchell lecture 1979. J R Coll Physicians Lond (1980) 0.97
The early bactericidal activity of amikacin in pulmonary tuberculosis. Int J Tuberc Lung Dis (2001) 0.97
Efficacy of intermittent pyrazinamide in experimental murine tuberculosis. Tubercle (1991) 0.96
The contribution of hydrogen peroxide resistance to virulence of Mycobacterium tuberculosis during the first six days after intravenous infection of normal and BCG-vaccinated guinea-pigs. Br J Exp Pathol (1981) 0.95
A comparison of various measures of sensitivity of M. tubercolosis to pyrazinamide. Tubercle (1970) 0.92
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase. Int J Tuberc Lung Dis (2000) 0.92
The effect of pulsed exposures to rifampin on the uptake of uridine- 14 C by Mycobacterium tuberculosis. Am Rev Respir Dis (1972) 0.92